The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection - A pilot study

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 211-218

  Skov, Marianne ^a   Pressler, Tacjana ^a   Lykkesfeldt, Jens ^b   Poulsen, Henrik Enghusen ^c   Jensen, Peter Østrup ^a   Johansen, Helle Krogh ^a,e   Qvist, Tavs ^a   Kræmer, Dorthe ^d   Høiby, Niels ^a,b   Ciofu, Oana ^b  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Bispebjerg and Frederiksberg Hospitals   (Denmark)

^d Section of General Practice   (Denmark)

^e Chalmers University of Technology   (Denmark)

Author keywords

Antioxidants; Ascorbic acid; N acetylcysteine; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 ISOPROSTANE; 8 OXO 7,8 DIHYDROGUANOSINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ASCORBIC ACID; CREATININE; DEHYDROASCORBIC ACID; DEOXYGUANOSINE DERIVATIVE; GAMMA TOCOPHEROL; MALONALDEHYDE; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CYSTIC FIBROSIS; DRUG EFFECT; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; LUNG INFECTION; MALE; OPEN STUDY; OXIDATIVE STRESS; PILOT STUDY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY BURST; SHORT COURSE THERAPY; STOMACH PAIN; TREATMENT DURATION; URINALYSIS; VITAMIN BLOOD LEVEL; CHRONIC DISEASE; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; INFLAMMATION; LUNG; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ADULT; ANTIOXIDANTS; ASCORBIC ACID; CHRONIC DISEASE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; LUNG; MALE; MIDDLE AGED; OXIDATIVE STRESS; PSEUDOMONAS INFECTIONS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84924339893     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.09.015     Document Type: Article

References (47)

1. Hull J., Vervaart P., Grimwood K., Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997, 52(6):557-560.
2. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Gutierrez J.P., Hull J., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med Oct 1997, 156(4 Pt 1):1197-1204.
3. Sagel S.D., Sontag M.K., Wagener J.S., Kapsner R.K., Osberg I., Accurso F.J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr Dec 2002, 141(6):811-817.
4. Galli F., Battistoni A., Gambari R., Pompella A., Bragonzi A., Pilolli F., et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta May 2012, 1822(5):690-713.
5. Wood L.G., Fitzgerald D.A., Lee A.K., Garg M.L. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. Am J Clin Nutr 2003, 77(1):150-159.
6. Winklhofer-Roob B.M. Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance. Acta Paediatr Suppl Apr 1994, 83(395):49-57.
7. Winklhofer-Roob B.M., van't Hof M.A., Shmerling D.H. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. Am J Clin Nutr May 1996, 63(5):722-728.
8. Winklhofer-Roob B.M., Ellemunter H., Fruhwirth M., Schlegel-Haueter S.E., Khoschsorur G., van't Hof M.A., et al. Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. Am J Clin Nutr Jun 1997, 65(6):1858-1866.
9. Winklhofer-Roob B.M. Nutritional status in cystic fibrosis: where to go from here?. Am J Clin Nutr May 1998, 67(5):817-818.
10. Brown R.K., Kelly F.J. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 1994, 36(4):487-493.
11. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 2001, 30(12):1440-1461.
12. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol Dec 1993, 75(6):2419-2424.
13. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 2006, 103(12):4628-4633.
14. Rushworth G.F., Megson I.L. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther Feb 2014, 141(2):150-159.
15. Atkuri K.R., Mantovani J.J., Herzenberg L.A., Herzenberg L.A. N-acetylcysteine - a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol Aug 2007, 7(4):355-359.
16. Tam J., Nash E.F., Ratjen F., Tullis E., Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev 2013, 7:CD007168.
17. Stafanger G., Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur Respir J 1989, 2(3):234-237.
18. Griese M., Kappler M., Eismann C., Ballmann M., Junge S., Rietschel E., et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med Jul 1 2013, 188(1):83-89.
19. Winkler B.S., Orselli S.M., Rex T.S. The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med Oct 1994, 17(4):333-349.
20. Jensen P.O., Lykkesfeldt J., Bjarnsholt T., Hougen H.P., Hoiby N., Ciofu O. Poor antioxidant status exacerbates oxidative stress and inflammatory response to Pseudomonas aeruginosa lung infection in guinea pigs. Basic Clin Pharmacol Toxicol Apr 2012, 110(4):353-358.
21. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J Aug 2005, 26(2):319-338.
22. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol Feb 1993, 15(2):75-88.
23. Hankinson J.L., Odencrantz J.R., Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med Jan 1999, 159(1):179-187.
24. Lykkesfeldt J. Ascorbate and dehydroascorbic acid as biomarkers of oxidative stress: validity of clinical data depends on vacutainer system used. Nutr Res Jan 2012, 32(1):66-69.
25. Lykkesfeldt J. Ascorbate and dehydroascorbic acid as reliable biomarkers of oxidative stress: analytical reproducibility and long-term stability of plasma samples subjected to acidic deproteinization. Cancer Epidemiol Biomarkers Prev Nov 2007, 16(11):2513-2516.
26. Lykkesfeldt J. Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem Sep 2001, 47(9):1725-1727.
27. Sattler W., Mohr D., Stocker R. Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol 1994, 233:469-489.
28. Henriksen T., Hillestrom P.R., Poulsen H.E., Weimann A. Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-2'-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandem mass spectrometry. Free Radic Biol Med Sep 1 2009, 47(5):629-635.
29. Rothe G., Oser A., Valet G. Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften Jul 1988, 75(7):354-355.
30. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther Dec 2008, 8(12):1955-1962.
31. Burton G.W., Wronska U., Stone L., Foster D.O., Ingold K.U. Biokinetics of dietary RRR-alpha-tocopherol in the male guinea pig at three dietary levels of vitamin C and two levels of vitamin E. Evidence that vitamin C does not "spare" vitamin E in vivo. Lipids Apr 1990, 25(4):199-210.
32. Ford E.S., Schleicher R.L., Mokdad A.H., Ajani U.A., Liu S. Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. Am J Clin Nutr Aug 2006, 84(2):375-383.
33. Farrell P.M., Bieri J.G., Fratantoni J.F., Wood R.E., di Sant'Agnese P.A. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. J Clin Invest Jul 1977, 60(1):233-241.
34. Benabdeslam H., Abidi H., Garcia I., Bellon G., Gilly R., Revol A. Lipid peroxidation and antioxidant defenses in cystic fibrosis patients. Clin Chem Lab Med May 1999, 37(5):511-516.
35. Sagel S.D., Sontag M.K., Anthony M.M., Emmett P., Papas K.A. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst Fibros Jan 2011, 10(1):31-36.
36. Lagrange-Puget M., Durieu I., Ecochard R., bbas-Chorfa F., Steghens J.P., et al. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation. Pediatr Pulmonol 2004, 38(1):43-49.
37. Brown R.K., Kelly F.J. Role of free radicals in the pathogenesis of cystic fibrosis. Thorax Aug 1994, 49(8):738-742.
38. Brown R.K., McBurney A., Lunec J., Kelly F.J. Oxidative damage to DNA in patients with cystic fibrosis. Free Radic Biol Med Apr 1995, 18(4):801-806.
39. Winklhofer-Roob B.M., Ziouzenkova O., Puhl H., Ellemunter H., Greiner P., Muller G., et al. Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. Free Radic Biol Med Dec 1995, 19(6):725-733.
40. Dominguez C., Gartner S., Linan S., Cobos N., Moreno A. Enhanced oxidative damage in cystic fibrosis patients. Biofactors 1998, 8(1-2):149-153.
41. Portal B.C., Richard M.J., Faure H.S., Hadjian A.J., Favier A.E. Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr Apr 1995, 61(4):843-847.
42. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., Collins C.E., Garg M.L. Oxidative stress in cystic fibrosis: dietary and metabolic factors. J Am Coll Nutr 2001, 20(2 Suppl.):157-165.
43. Collins C.E., Quaggiotto P., Wood L., O'Loughlin E.V., Henry R.L., Garg M.L. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids Jun 1999, 34(6):551-556.
44. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clin Chim Acta May 1 2007, 380(1-2):50-58.
45. Stick S.M., Brennan S., Murray C., Douglas T., von Ungern-Sternberg B.S., Garratt L.W., et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr Nov 2009, 155(5):623-628.
46. Sly P.D., Brennan S., Gangell C., De K.N., Murray C., Mott L., et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med Jul 15 2009, 180(2):146-152.
47. Stick S.M. The first 2years of life: implications of recent findings. Curr Opin Pulm Med Nov 2009, 15(6):615-620.